• PharmaJet will deliver three presentations covering programs using Tropis^®, its Intradermal (ID) Needle-free Injection System.
• Tropis ID makes intradermal delivery efficient^1,2, while reducing pain³ and adverse events.⁴
• Used for over 12 million pediatric injections, Tropis ID continues to benefit the Global Polio Eradication Initiative.

PharmaJet^®, a company that strives to improve the performance and outcomes of injectables with its needle-free injection technology, will present at the American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting, November 9-13, at the Metro Toronto Convention Centre in Toronto, Ontario, Canada. The meeting brings together the largest international scientific organization of experts dedicated to reducing the worldwide burden of tropical infectious diseases and improving global health. PharmaJet will share why an increasing number of drug developers are exploring the benefits that Tropis intradermal delivery brings to their injectable product development programs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104841971/en/

Healthcare workers in Nigeria receive training on the use of the Tropis ID Needle-free System.

Paul LaBarre, Senior Vice President of Global Business Development will present the following:

• “Novel technologies for intradermal delivery of fractional-dose inactivated poliomyelitis vaccine: Review of implementation research and implications for equitable neglected tropical disease vaccine access”; Monday, November 10; 12:30 p.m. – 2:15 p.m. United States/Canada Eastern Time Zone
• “Evaluating the Impact of Needle-free Intradermal Delivery of Inactivated Polio Vaccine in Nigeria’s Routine Immunization Program”; Tuesday, November 11; 12:00 Noon – 1:45 p.m.
• “Novel non-invasive vaccine delivery practices may increase access and acceptability of latent tuberculosis infection screening”; Wednesday, November 12; 11:00 a.m. – 12:45 p.m.

“Needles have been associated with pain, adverse events, and hesitation. Our needle-free systems have been validated with over 12 million injections, and our partners are finding new ways to leverage the precision, acceptability, and other unique benefits of needle-free to make their candidate products even better,” said Paul LaBarre, Senior Vice President of Global Business Development at PharmaJet. “While our patented needle-free technology has been shown to improve immunization coverage with high acceptability and cost-effectiveness² it is our pharmaceutical partner data that really excite us – when they discover the immunological benefits of intradermal delivery and develop new strategies to optimize their candidate products using Tropis.”

For more information about partnering with PharmaJet, please look for us at one of these presentations or go to the PharmaJet website: https://www.pharmajet.com.

Refer to Instructions for Use to ensure safe injections and to review risks.

About PharmaJet

The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis^® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis^® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. PharmaJet’s most recent innovation is focused on the development of new platforms optimized for self-administration of subcutaneous delivered chronic disease treatments (single-use and reusable platforms). For more information or if you are interested in partnering with PharmaJet visit https://www.pharmajet.com or contact PharmaJet here. Follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251104841971/en/